Celerion Appoints New Executive Director
News May 22, 2013
Dr. Morimoto will have responsibility for developing and implementing strategies for patient populations in early clinical research and clinical pharmacology studies. Dr. Morimoto will also assume leadership for the External Studies Management and Clinical Monitoring Services teams.
The appointment of Dr. Morimoto reinforces Celerion’s focus on delivering Applied Translational Medicine. Celerion is focused on applying our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
Dr. Morimoto comes to Celerion with over 20 years of experience in the pharmaceutical and biotechnology industries as well as in contract research organizations (CRO). Prior to joining Celerion, he was Vice President of Drug Development at Allon Therapeutics, where his focus was to manage their neurodegeneration and dementia therapeutic programs including preclinical, manufacturing and clinical development. Dr. Morimoto also held positions at MDS Pharma Services, a full service CRO; Neuromed Technologies, a biotech company developing novel pain therapeutics; Phoenix International Life Sciences, a global CRO; and Amur Pharmaceuticals, a biopharmaceutical company focused on diabetes and drug delivery research.
Dr. Morimoto’s hands-on drug development experience that includes program, project and portfolio management, combined with an understanding of the CRO industry, provides him with invaluable insight into how best to tackle the inclusion of patients in both clinical pharmacology as well as Phase IIa Proof-of-Concept studies.
“We are very pleased to have Bruce join the Drug Development Services team at Celerion,” said Susan Thornton Ph.D, President and CEO of Celerion. “His in-depth knowledge of drug development as well as focus on Applied Translational Medicine from both the client and CRO perspective will be a great asset to our organization.”
Dr. Morimoto earned his doctorate in biochemistry from the University of California, Los Angeles (UCLA), completed post doctorate research at University of California, Berkeley, and was also on the faculty in the Chemistry department at Purdue University.
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE